Day One Biopharmaceuticals Inc. (DAWN) saw its stock soar by 5.04% in pre-market trading on Monday, following the announcement of new data for its lead product candidate, OJEMDA™ (tovorafenib). The company revealed that updated results from its Phase 2 FIREFLY-1 trial will be presented at the upcoming Society for Neuro-Oncology (SNO) Annual Meeting, showcasing the drug's potential in treating pediatric low-grade glioma (pLGG).

The oral presentation, scheduled for November 23, 2025, will feature more than 36 months of follow-up data from the FIREFLY-1 trial. This study evaluates tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pLGG harboring a known activating BRAF alteration. The data is expected to demonstrate durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval information.

Investors are reacting positively to this news, as it suggests OJEMDA's potential efficacy in treating this challenging form of pediatric brain cancer. The durability of responses and the possibility of treatment-free intervals are particularly encouraging, as they could significantly improve the quality of life for young patients. As Day One Biopharmaceuticals continues to advance its pipeline, the market appears optimistic about the company's prospects in the pediatric oncology space.